Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Dasatinib by Bristol-Myers Squibb for Non-Small Cell Lung Cancer: Likelihood of Approval
Dasatinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Data Insights
Dasatinib by Bristol-Myers Squibb for Breast Cancer: Likelihood of Approval
Dasatinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Breast Cancer. According to GlobalData, Phase...